Kite Pharma, Inc. Comprehensive Income
Kite Pharma, Inc. reported Comprehensive Income of -$109.43 million for the 3-month period ending 2017-06-30, per its 10-Q filed 2017-08-08.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2017-08-08
- Kite Pharma, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2017-06-30 was -$109.43M.
- Kite Pharma, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2017-03-31 was -$90.17M.
- Kite Pharma, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2016-12-31 was -$86.53M.
- Kite Pharma, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2016-09-30 was -$74.03M.
- Kite Pharma, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2016 was -$267.77M.
- Kite Pharma, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2015 was -$101.58M.
- Kite Pharma, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2014 was -$42.87M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2017-06-30 | -$109.43M 10-Q · filed 2017-08-08 | -$199.60M 10-Q · filed 2017-08-08 | -$286.13M derived: sum of 3 quarters · filed 2017-08-08 | -$360.16M derived: sum of 4 quarters · filed 2017-08-08 |
| 2017-03-31 | -$90.17M 10-Q · filed 2017-05-08 | -$176.69M derived: sum of 2 quarters · filed 2017-05-08 | -$250.73M derived: sum of 3 quarters · filed 2017-05-08 | -$315.26M derived: sum of 4 quarters · filed 2017-08-08 |
| 2016-12-31 | -$86.53M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$160.56M derived: sum of 2 quarters · filed 2017-02-28 | -$225.10M derived: sum of 3 quarters · filed 2017-08-08 | -$267.77M 10-K · filed 2017-02-28 |
| 2016-09-30 | -$74.03M 10-Q · filed 2016-11-09 | -$138.57M derived: sum of 2 quarters · filed 2017-08-08 | -$181.24M 10-Q · filed 2016-11-09 | -$220.16M derived: sum of 4 quarters · filed 2017-08-08 |
| 2016-06-30 | -$64.54M 10-Q · filed 2017-08-08 | -$107.21M 10-Q · filed 2017-08-08 | -$146.13M derived: sum of 3 quarters · filed 2017-08-08 | -$173.44M derived: sum of 4 quarters · filed 2017-08-08 |
| 2016-03-31 | -$42.67M 10-Q · filed 2017-05-08 | -$81.59M derived: sum of 2 quarters · filed 2017-05-08 | -$108.90M derived: sum of 3 quarters · filed 2017-05-08 | |
| 2015-12-31 | -$38.92M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$66.23M derived: sum of 2 quarters · filed 2017-02-28 | -$101.58M 10-K · filed 2017-02-28 | |
| 2015-09-30 | -$27.31M 10-Q · filed 2016-11-09 | -$62.65M 10-Q · filed 2016-11-09 | ||
| 2014-12-31 | -$42.87M 10-K · filed 2017-02-28 |